OTCMKTS:SNNAQ

Sienna Biopharmaceuticals Competitors

$0.03
-0.01 (-20.63 %)
(As of 04/20/2021 05:19 PM ET)
Add
Compare
Today's Range
$0.02
Now: $0.03
$0.03
50-Day Range
$0.02
MA: $0.03
$0.04
52-Week Range
$0.00
Now: $0.03
$0.07
Volume40,855 shs
Average Volume131,458 shs
Market Capitalization$581,456.80
P/E RatioN/A
Dividend YieldN/A
Beta1.73

Competitors

Sienna Biopharmaceuticals (OTCMKTS:SNNAQ) Vs. VVUSQ, IMUCD, NSPX, ETST, BTHE, and IMUC

Should you be buying SNNAQ stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to Sienna Biopharmaceuticals, including VIVUS (VVUSQ), ImmunoCellular Therapeutics (IMUCD), Inspyr Therapeutics (NSPX), Earth Science Tech (ETST), Boston Therapeutics (BTHE), and ImmunoCellular Therapeutics (IMUC).

Sienna Biopharmaceuticals (OTCMKTS:SNNAQ) and VIVUS (OTCMKTS:VVUSQ) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, risk, profitability, earnings and valuation.

Analyst Recommendations

This is a summary of current ratings and recommmendations for Sienna Biopharmaceuticals and VIVUS, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Sienna Biopharmaceuticals0000N/A
VIVUS0000N/A

Risk and Volatility

Sienna Biopharmaceuticals has a beta of 1.73, meaning that its share price is 73% more volatile than the S&P 500. Comparatively, VIVUS has a beta of -3.25, meaning that its share price is 425% less volatile than the S&P 500.

Earnings and Valuation

This table compares Sienna Biopharmaceuticals and VIVUS's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Sienna BiopharmaceuticalsN/AN/A$-73,470,000.00N/AN/A
VIVUS$69.76 million0.03$-31,500,000.00($2.96)-0.04

VIVUS has higher revenue and earnings than Sienna Biopharmaceuticals.

Profitability

This table compares Sienna Biopharmaceuticals and VIVUS's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Sienna BiopharmaceuticalsN/AN/AN/A
VIVUS-39.28%N/A-12.18%

Institutional and Insider Ownership

7.3% of VIVUS shares are owned by institutional investors. 27.2% of Sienna Biopharmaceuticals shares are owned by company insiders. Comparatively, 12.0% of VIVUS shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

Sienna Biopharmaceuticals beats VIVUS on 4 of the 7 factors compared between the two stocks.

Sienna Biopharmaceuticals (OTCMKTS:SNNAQ) and ImmunoCellular Therapeutics (OTCMKTS:IMUCD) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, dividends, valuation, profitability, risk, analyst recommendations and institutional ownership.

Profitability

This table compares Sienna Biopharmaceuticals and ImmunoCellular Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Sienna BiopharmaceuticalsN/AN/AN/A
ImmunoCellular TherapeuticsN/AN/AN/A

Valuation and Earnings

This table compares Sienna Biopharmaceuticals and ImmunoCellular Therapeutics' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Sienna BiopharmaceuticalsN/AN/A$-73,470,000.00N/AN/A
ImmunoCellular TherapeuticsN/AN/A$-14,310,000.00N/AN/A

Analyst Recommendations

This is a breakdown of recent ratings and price targets for Sienna Biopharmaceuticals and ImmunoCellular Therapeutics, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Sienna Biopharmaceuticals0000N/A
ImmunoCellular Therapeutics0000N/A

Volatility & Risk

Sienna Biopharmaceuticals has a beta of 1.73, meaning that its stock price is 73% more volatile than the S&P 500. Comparatively, ImmunoCellular Therapeutics has a beta of 1.63, meaning that its stock price is 63% more volatile than the S&P 500.

Inspyr Therapeutics (OTCMKTS:NSPX) and Sienna Biopharmaceuticals (OTCMKTS:SNNAQ) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, earnings, valuation, risk, dividends, analyst recommendations and institutional ownership.

Analyst Recommendations

This is a summary of recent recommendations for Inspyr Therapeutics and Sienna Biopharmaceuticals, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Inspyr Therapeutics0000N/A
Sienna Biopharmaceuticals0000N/A

Profitability

This table compares Inspyr Therapeutics and Sienna Biopharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Inspyr TherapeuticsN/AN/A-298.11%
Sienna BiopharmaceuticalsN/AN/AN/A

Risk & Volatility

Inspyr Therapeutics has a beta of -16.55, suggesting that its share price is 1,755% less volatile than the S&P 500. Comparatively, Sienna Biopharmaceuticals has a beta of 1.73, suggesting that its share price is 73% more volatile than the S&P 500.

Earnings and Valuation

This table compares Inspyr Therapeutics and Sienna Biopharmaceuticals' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Inspyr TherapeuticsN/AN/A$-930,000.00N/AN/A
Sienna BiopharmaceuticalsN/AN/A$-73,470,000.00N/AN/A

Summary

Sienna Biopharmaceuticals beats Inspyr Therapeutics on 2 of the 3 factors compared between the two stocks.

Sienna Biopharmaceuticals (OTCMKTS:SNNAQ) and Earth Science Tech (OTCMKTS:ETST) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, valuation, earnings, dividends, institutional ownership, risk and profitability.

Volatility and Risk

Sienna Biopharmaceuticals has a beta of 1.73, suggesting that its stock price is 73% more volatile than the S&P 500. Comparatively, Earth Science Tech has a beta of 2.53, suggesting that its stock price is 153% more volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of recent ratings for Sienna Biopharmaceuticals and Earth Science Tech, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Sienna Biopharmaceuticals0000N/A
Earth Science Tech0000N/A

Earnings & Valuation

This table compares Sienna Biopharmaceuticals and Earth Science Tech's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Sienna BiopharmaceuticalsN/AN/A$-73,470,000.00N/AN/A
Earth Science Tech$530,000.003.39$-1,200,000.00N/AN/A

Earth Science Tech has higher revenue and earnings than Sienna Biopharmaceuticals.

Profitability

This table compares Sienna Biopharmaceuticals and Earth Science Tech's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Sienna BiopharmaceuticalsN/AN/AN/A
Earth Science Tech-1,750.31%N/A-2,929.76%

Summary

Earth Science Tech beats Sienna Biopharmaceuticals on 3 of the 5 factors compared between the two stocks.

Boston Therapeutics (OTCMKTS:BTHE) and Sienna Biopharmaceuticals (OTCMKTS:SNNAQ) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, profitability, institutional ownership, risk, dividends, valuation and earnings.

Volatility and Risk

Boston Therapeutics has a beta of -0.16, suggesting that its share price is 116% less volatile than the S&P 500. Comparatively, Sienna Biopharmaceuticals has a beta of 1.73, suggesting that its share price is 73% more volatile than the S&P 500.

Analyst Ratings

This is a summary of recent ratings and recommmendations for Boston Therapeutics and Sienna Biopharmaceuticals, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Boston Therapeutics0000N/A
Sienna Biopharmaceuticals0000N/A

Profitability

This table compares Boston Therapeutics and Sienna Biopharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Boston Therapeutics-24,627.27%N/A-3,480.61%
Sienna BiopharmaceuticalsN/AN/AN/A

Earnings and Valuation

This table compares Boston Therapeutics and Sienna Biopharmaceuticals' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Boston Therapeutics$20,000.0087.24$-3,690,000.00N/AN/A
Sienna BiopharmaceuticalsN/AN/A$-73,470,000.00N/AN/A

Boston Therapeutics has higher revenue and earnings than Sienna Biopharmaceuticals.

Summary

Sienna Biopharmaceuticals beats Boston Therapeutics on 3 of the 5 factors compared between the two stocks.

ImmunoCellular Therapeutics (OTCMKTS:IMUC) and Sienna Biopharmaceuticals (OTCMKTS:SNNAQ) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, dividends, profitability, valuation, risk and earnings.

Profitability

This table compares ImmunoCellular Therapeutics and Sienna Biopharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
ImmunoCellular TherapeuticsN/AN/AN/A
Sienna BiopharmaceuticalsN/AN/AN/A

Valuation and Earnings

This table compares ImmunoCellular Therapeutics and Sienna Biopharmaceuticals' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ImmunoCellular TherapeuticsN/AN/AN/AN/AN/A
Sienna BiopharmaceuticalsN/AN/A$-73,470,000.00N/AN/A

Analyst Ratings

This is a summary of current ratings and target prices for ImmunoCellular Therapeutics and Sienna Biopharmaceuticals, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
ImmunoCellular Therapeutics0000N/A
Sienna Biopharmaceuticals0000N/A

Risk and Volatility

ImmunoCellular Therapeutics has a beta of 1.61, indicating that its stock price is 61% more volatile than the S&P 500. Comparatively, Sienna Biopharmaceuticals has a beta of 1.73, indicating that its stock price is 73% more volatile than the S&P 500.

Summary

Sienna Biopharmaceuticals beats ImmunoCellular Therapeutics on 1 of the 1 factors compared between the two stocks.


Sienna Biopharmaceuticals Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
VVUSQ
VIVUS
0.6$0.12-0.0%$2.10 million$69.76 million-0.04
IMUCD
ImmunoCellular Therapeutics
0.0$0.45-9.0%$1.87 millionN/A0.00Gap Up
NSPX
Inspyr Therapeutics
0.5$0.01-14.0%$1.83 millionN/A0.00
Earth Science Tech logo
ETST
Earth Science Tech
0.5$0.04-0.6%$1.78 million$530,000.000.00
Boston Therapeutics logo
BTHE
Boston Therapeutics
0.5$0.02-2.5%$1.70 million$20,000.00-0.79Gap Down
ImmunoCellular Therapeutics logo
IMUC
ImmunoCellular Therapeutics
0.0$0.50-11.0%$1.57 millionN/A0.00News Coverage
Gap Up
Cardax logo
CDXI
Cardax
0.0$1.95-2.6%$1.55 million$710,000.000.00High Trading Volume
Gap Up
MLNTQ
Melinta Therapeutics
0.2$0.11-0.0%$1.51 million$96.43 million0.00
HSTC
HST Global
0.8$0.26-7.7%$1.36 millionN/A0.00Gap Down
WWHC
W World
0.8$4.90-8.2%$1.33 millionN/A0.00
Achaogen logo
AKAOQ
Achaogen
0.6$0.03-0.4%$1.29 million$8.73 million0.00Gap Up
Propanc Biopharma logo
PPCB
Propanc Biopharma
0.7$0.21-4.5%$1.17 millionN/A0.00Decrease in Short Interest
Gap Up
Cotinga Pharmaceuticals logo
COTQF
Cotinga Pharmaceuticals
0.4$0.25-79.4%$1.12 millionN/A-2.76Upcoming Earnings
Gap Down
AOXG
Aoxing Pharmaceutical
0.5$0.01-13.0%$991,000.00N/A0.00Gap Down
TetraLogic Pharmaceuticals logo
TLOG
TetraLogic Pharmaceuticals
0.5$0.04-1.3%$978,000.00N/A0.00Gap Up
AOLS
Aeolus Pharmaceuticals
0.8$0.01-3.3%$928,000.00N/A0.00Gap Up
ATRX
Adhera Therapeutics
0.0$0.06-7.1%$872,000.00$250,000.000.00Gap Down
Anthera Pharmaceuticals logo
ANTH
Anthera Pharmaceuticals
0.5$0.07-8.1%$865,000.00N/A0.00Gap Up
PXYN
Praxsyn
0.6$0.00-10.0%$763,000.00N/A0.00Gap Down
SPHS
Sophiris Bio
0.1$0.02-6.7%$739,000.00N/A0.00Gap Down
Argos Therapeutics logo
ARGSQ
Argos Therapeutics
0.6$0.05-0.0%$572,000.00$1.90 million0.00
TRPXD
Therapix Biosciences
0.0$9.20-0.5%$460,000.00N/A0.00High Trading Volume
BSPM
Biostar Pharmaceuticals
0.0$0.16-5.6%$399,000.00N/A0.00Gap Up
SKVI
Skinvisible
0.7$0.10-11.6%$376,000.00$40,000.000.00
EPRSQ
EPIRUS Biopharmaceuticals
0.5$0.01-2.0%$366,000.00N/A0.00Gap Down
Spotlight Innovation logo
STLT
Spotlight Innovation
0.5$0.01-0.0%$343,000.00N/A0.00
ProMetic Life Sciences logo
PFSCF
ProMetic Life Sciences
0.5$5.47-3.7%$338,000.00$36.55 million0.00Gap Up
WDBG
Woodbrook Group
0.0$1.60-0.0%$224,000.00N/A0.00
ROSGQ
Rosetta Genomics
0.0$0.08-21.2%$183,000.00N/A0.00
PZRXQ
PhaseRx
0.2$0.03-47.2%$175,000.00N/A0.00
OREXQ
Orexigen Therapeutics
0.4$0.01-26.4%$100,000.00$33.71 million0.00Gap Up
MetaStat logo
MTST
MetaStat
0.0$0.01-0.7%$82,000.00$20,000.000.00
AXMP
AXM Pharma
0.2$0.00-0.0%$81,000.00N/A0.00
ALSE
Alseres Pharmaceuticals
0.0$6.00-0.0%$36,000.00N/A0.00
BOPH
Bohai Pharmaceuticals Group
0.5$0.00-0.0%$20,000.00N/A0.00
Immune Therapeutics logo
IMUN
Immune Therapeutics
0.6$0.02-3.3%$7,000.00$110,000.000.00Gap Up
Acusphere logo
ACUS
Acusphere
0.0$0.05-2.2%$0.00N/A0.00Gap Down
Affymax logo
AFFY
Affymax
0.6$0.10-17.3%$0.00N/A0.00Gap Down
AOBI
American Oriental Bioengineering
0.4$1.50-0.0%$0.00N/A0.00
ARYX
ARYx Therapeutics
0.0$0.02-67.5%$0.00N/A0.00High Trading Volume
Gap Down
AHROQ
AtheroNova
0.0$0.01-0.0%$0.00N/A0.00
CBPI
China Botanic Pharmaceutical
0.0$0.07-0.0%$0.00N/A0.00Gap Down
China Dongsheng International logo
CDSG
China Dongsheng International
0.3$0.01-0.0%$0.00N/A0.00
China Health Industries logo
CHHE
China Health Industries
0.4$0.49-0.0%$0.00$9.93 million8.13
DDXSQ
Diadexus
0.0N/AN/A$0.00N/A0.00
ERBA
ERBA Diagnostics
0.8$0.04-0.0%$0.00N/A0.00
FTCY
Global Future City
0.5$0.00-0.0%$0.00N/A0.00
GLSI
Greenwich LifeSciences
2.0$32.02-3.9%$0.00N/A0.00Decrease in Short Interest
Gap Up
HRBR
Harbor Diversified
0.0$1.13-13.8%$0.00$263.61 million0.00
IPAH
Interpharm
0.2$0.00-25.0%$0.00N/A0.00Gap Up
This page was last updated on 4/20/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.